Eligibility of all registered patients
Following our inclusion/exclusion criteria derived from Phase III trials
of DOACs (Table 1), 4054 (51.8%) patients with NVAF were classified as
the eligible group, whereas the remaining patients (n=3772, 48.2%) were
classified as the ineligible group mainly because of
CHADS2 score <2 (26.4%), renal dysfunction
(9.5%), anaemia (6.4%), and chronic treatment with nonsteroidal
anti-inflammatories (NSAIDs (4.0%) (Table
2 ).14